Shanghai Haohai Biological Technology Co (HKSE:06826) 3-Year EBITDA Growth Rate : 20.10% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate?

Shanghai Haohai Biological Technology Co's EBITDA per Share for the three months ended in Mar. 2024 was HK$0.75.

During the past 12 months, Shanghai Haohai Biological Technology Co's average EBITDA Per Share Growth Rate was 98.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 20.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Haohai Biological Technology Co was 28.70% per year. The lowest was -12.50% per year. And the median was 10.40% per year.

Competitive Comparison of Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate falls into.

Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shanghai Haohai Biological Technology Co (HKSE:06826) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shanghai Haohai Biological Technology Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

688366:China

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines